Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Immutep.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Patrys, Immutep jump after reports show drugs well tolerated
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise, Immutep surges 46pc on trial results
Health & Biotech
ASX Health Stocks: FDA approves Imugene’s Phase 1 trial; Noxopharm says it can fight skin disease
News
ASX Small Caps Market Wrap: What shifty trick have those jokesters at Qantas come up with this morning?
Health & Biotech
ASX Health Stocks: Rhythym Bio skyrockets 70pc after being granted UK CA Mark
News
Market Highlights: China to benefit from a possible US default, and 5 ASX small caps to watch today
News
Market Highlights: JPMorgan bids for First Republic, Exxon’s record profit, and 5 ASX small caps to watch on Monday
News
Market Highlights: New banking crisis as First Republic seeks a lifeline; and 5 ASX small caps to watch today
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
Could immunotherapy replace chemo? Here’s one stock that could rise 5x according to broker
Health & Biotech
ASX Health Stocks: Cannabis play ECS Botanics enters burgeoning German market, share price up 20pc
News
Market Highlights: Tesla, oil prices slump, and 5 ASX small caps to watch on Wednesday
Health & Biotech
ASX Health Stocks: Imagion jumps 20pc after delivering positive Phase 1 results
News
Market Highlights: Rates day! And almost every US stock loses overnight as US economy picks up
Health & Biotech
ScoPo’s Powerplays: ASX health stocks dancing to a positive tune
Health & Biotech
Check Up: The world’s most expensive drug costs $3.5 MILLION a shot – and there’s an Aussie company behind it
Health & Biotech